New Study Identifies Distinct Entity in Pachychoroid Disease: Pachyvitelliform Maculopathy

The study published in The British Journal of Ophthalmology was a retrospective, multicenter, observational analysis, involving the review of medical records and multimodal imaging of patients with pachychoroid disease and AVL. Seventeen eyes of 17 patients were included in the PVM group, with a mean age of 71.41 years. The average follow-up period was 33.15 months.

Key findings from the study include:

• Visual Acuity (VA): Baseline VA in the PVM group was 20/40, which declined to 20/100 during the follow-up period.

• Pachyvessels and AVL: All AVLs were detected overlying pachyvessels using optical coherence tomography (OCT) and were hyperautofluorescent with fundus autofluorescent imaging.

• Choroidal Thickness: The mean central choroidal thickness (CCT) in the PVM group was significantly greater at 352.35 µm compared to 226.88 µm in the control group (p<0.001).

• RPE Dysfunction and Atrophy: Retinal pigment epithelium disruption was present in 64.71% of eyes with PVM at baseline, and 41.18% developed macular atrophy by the end of the follow-up period.

The researchers suggest a possible pathogenesis of RPE dysfunction in PVM, which may be related to the thick choroid in affected eyes. This could lead to the accumulation of undigested photoreceptor outer segments and the formation of AVL. Clinicians should be aware of this common cause of vitelliform lesions and the poor visual prognosis due to the high risk of atrophy development.

Pachyvitelliform maculopathy is an important addition to the spectrum of pachychoroid disease, and understanding its distinct features can aid in accurate diagnosis and appropriate management. As the study highlights the association between choroidal thickness and RPE dysfunction, further research may shed light on potential treatment strategies to address this visual impairment effectively.

Early detection and intervention are crucial in managing PVM, and ophthalmologists should remain vigilant in recognizing the signs and symptoms of this condition to provide timely care and optimize patient outcomes. Future studies may explore potential therapeutic approaches to address RPE dysfunction and prevent or slow down the development of macular atrophy in PVM patients.

Reference:

Hilely, A., Au, A., Lee, W. K., Fogel Levin, M., Zur, D., Romero-Morales, V., Santina, A., Lee, J. S., Loewenstein, A., & Sarraf, D. (2023). Pachyvitelliform maculopathy: an optical coherence tomography analysis of a novel entity. The British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2022-322553